Faculty Presenter and Course Chair
Stephanie L. Wethington, MD, MSc
Assistant Professor of Gynecology and Obstetrics
Johns Hopkins University School of Medicine
Additional Content Development Faculty
Andrea R. Hagemann, MD, MSCI
Associate Professor of Obstetrics and Gynecology
Washington University School of Medicine
St. Louis, Missouri
Barbara S. Norquist, MD
Assistant Professor of Obstetrics and Gynecology
University of Washington School of Medicine
Medical Director, Breast and Ovarian Cancer Prevention Program
Seattle Cancer Care Alliance
Ovarian cancer is the fifth most common cause of cancer death in women in the United States. The majority of patients with ovarian cancer experience disease recurrence and receive second-line and sometimes several lines of therapy. Recurrent ovarian cancer is often resistant to chemotherapy, thus limiting the treatment options. Advances in technology and medical research have identified VEGF and PARP as targets for therapy, leading to the development of antiangiogenesis agents and PARP inhibitors. This activity will examine novel targeted therapy for recurrent advanced ovarian cancer.
AGENDA and PROGRAM GOALS
• Introduction (5 minutes)
• Inhibition of angiogenesis (5 minutes)
• Homologous recombination deficiency (HRD) (5 minutes)
• Role of PARP inhibition in cancer (5 minutes)
• Role of PARP inhibitors in recurrent advanced ovarian cancer (15 minutes)
• Adverse events with PARP inhibitors (10 minutes)
• Importance of patient education and adherence to therapy (5 minutes)
• Cases and conclusions (10 minutes)
Presented by the Johns Hopkins University School of Medicine in collaboration with MCM Education.
This activity is intended for oncologists, gynecologists, and other clinicians including nurse practitioners (NPs), physician assistants (PAs), and nurses who encounter patients with ovarian cancer. There are no prerequisites for this activity.
After attending this activity, the participant will demonstrate the ability to:
- Discuss the role of angiogenesis inhibitors in the management of recurrent advanced ovarian cancer.
- Discuss the role of homologous recombination (HR) deficiency in the development of recurrent advanced ovarian cancer.
- Describe the mechanism of action, efficacy, and safety of PARP inhibitors approved to treat advanced ovarian cancer.
- Outline the management of patients with recurrent advanced ovarian cancer by incorporating angiogenesis inhibitors or PARP inhibitors into a management program.
- Outline strategies for engaging patients about PARP inhibitor use to promote adherence to therapy.
METHOD OF PARTICIPATION/HOW TO RECEIVE CREDIT
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Review all modules associated with this course.
- Successfully complete the post-test (80% accuracy).
- Complete the CME/CE evaluation.
- The estimated time to complete this activity is 1.0 hour.
- Upon successful completion, your CME/CE certificate will be available to print for your records.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.
POLICY ON PRESENTER AND PROVIDER DISCLOSURE
It is the policy of the Johns Hopkins University School of Medicine that the presenter and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.
FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.
The following relationships have been reported for this activity:
Stephanie L. Wethington, MD, MSc, has disclosed she is Principal Investigator on a research grant funded by AstraZeneca.
No one else in a position to control the content of this educational activity has disclosed a relevant financial interest or relationship with any commercial interest.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Off-Label Product Discussion: No off-label products discussed.
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Johns Hopkins University School of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Commercial Support Statements
This activity is supported by independent educational grants from AstraZeneca and Tesaro, Inc.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protecting the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public.
Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OPINIONS AND OFF-LABEL DISCUSSIONS
In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.
CONFIDENTIALITY DISCLAIMER FOR CME/CE ACTIVITY PARTICIPANTS
I certify that I am participating in a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to “protected health information,” as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person’s health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (e.g., Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.
For CME Questions, please contact the CME Office (410) 502-9636 or e-mail firstname.lastname@example.org. For CME Certificates, please call (410) 502-9636.
Johns Hopkins University School of Medicine, Office of Continuing Medical Education, Turner 20/720 Rutland Avenue, Baltimore, Maryland 21205-2195. Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)
©2019. All rights reserved – The Johns Hopkins University School of Medicine.
Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:
The Materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without prior written permission.
To participate in additional CME activities presented by the Johns Hopkins University School of Medicine Continuing Medical Education Office, please visit https://hopkinscme.cloud-cme.com.
Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
Windows XP or above running Internet Explorer 7 (service pack 2) or above.
MAC OSX 10.5 (Leopard) or above running Safari 5.1 or above, or any version of Chrome, Firefox or Opera published in the last two years.
A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
Any Apple iPad or iPad Mini running iOS 5 or above.
Most high-performance Android tablets such as the Kindle Fire or Samsung Galaxy S.